India's pharmaceutical and healthcare sectors are set to report steady revenue growth of 8-10% in Q4 FY26, according to various brokerage estimates. However, profitability is likely to be affected by weak performance in the US generics market and rising operational costs. Motilal Oswal forecasts a 9% revenue growth alongside a 5.4% increase in earnings before interest, taxes, depreciation, and amortization (Ebitda). Analysts are divided on profit after tax (PAT) predictions, with some expecting a 6% decline while others anticipate a 9% growth. The pressure on margins is attributed to the poor performance of generics like Revlimid and increased spending on marketing and research and development, especially related to the launch of semaglutide in India. Despite these challenges, domestic formulation sales are expected to grow 13%, driven by a recovery in chronic therapies. Healthcare providers are also projected to deliver strong revenue growth, with Apollo Hospitals and Max Healthcare expected to see revenue increases of 14% and 16%, respectively. Overall, while the revenue outlook remains positive, the sector faces significant challenges that could impact profitability in the near term.